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Nanotechnology has made an important contribution to oncology in recent years,
especially for drug delivery. While many different nano-delivery systems have been
suggested for cancer therapy, selenium nanoparticles (SeNPs) are particularly promising
anticancer drug carriers as their core material offers interesting synergistic effects to
cancer cells. Se compounds can exert cytotoxic effects by acting as pro-oxidants that
alter cellular redox homeostasis, eventually leading to apoptosis induction in many kinds
of cancer cells. Herein, we report on the design and synthesis of novel layer-by-layer
Se-based nanocomplexes (LBL-Se-NCs) as carriers of small interfering RNA (siRNA) for
combined gene silencing and apoptosis induction in cancer cells. The LBL-Se-NCs were
prepared using a straightforward electrostatic assembly of siRNA and chitosan (CS) on
the solid core of the SeNP. In this study, we started by investigating the colloidal stability
and protection of the complexed siRNA. The results show that CS not only functioned
as an anchoring layer for siRNA, but also provided colloidal stability for at least 20 days
in different media when CS was applied as a third layer. The release study revealed that
siRNA remained better associated with LBL-Se-NCs, with only a release of 35% after
7 days, as compared to CS-NCs with a siRNA release of 100% after 48 h, making the
LBL nanocarrier an excellent candidate as an off-the-shelf formulation. When applied to
H1299 cells, it was found that they can selectively induce around 32% apoptosis, while
significantly less apoptosis (5.6%) was induced in NIH/3T3 normal cells. At the same
time, they were capable of efficiently inducing siRNA downregulation (35%) without loss
of activity 7 days post-synthesis. We conclude that LBL-Se-NCs are promising siRNA
carriers with enhanced stability and with a dual mode of action against cancer cells.
Keywords: selenium nanoparticle, cancer therapy, siRNA delivery, apoptosis, chitosan, nanomedicine, advanced
drug delivery
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INTRODUCTION
Nanotechnology has made important contributions to oncology
in recent years, thanks to its uniquely appealing features for drug
delivery, diagnosis, and imaging (Pucci et al., 2019). The use
of nanoparticles as drug delivery systems has the potential to
overcome some severe adverse effects induced by conventional
chemotherapeutic drugs on normal cells. Scientists have been
able to control the architecture of nanocarriers in such a way that
they can promote local delivery (targeting) and even controlled
drug release (Fritz and Lenardo, 2019; Martinelli et al., 2019).
According to their design, nanocarriers also have the capability of
packaging and protecting cargos that are toxic, fragile, insoluble,
or unstable for delivery as free drugs (Saw and Song, 2020).
Nanomaterials, including polymers, lipids, inorganic carriers,
polymeric hydrogels, and biomacromolecular scaffolds, have led
to the development of systems that can deliver chemotherapeutics
to tumor sites for achieving the intended therapeutic effect while
minimizing unwanted side effects (Shi et al., 2017; van der
Meel et al., 2019). Among the many nanomaterials, selenium
nanoparticles (SeNPs) are of increasing interest in cancer therapy.
Being an important trace element found in amino acids and
proteins, Se is necessary for mammalian life (Oldfield, 2002;
Zhang et al., 2009). In the 1960s, it entered the cancer field
with the development of Se-based radio labels, like sodium
selenite and selenomethionine, for cancer diagnosis (Cavalieri
and Scott, 1968; Lenardão et al., 2018). More recently, preclinical
studies and human clinical trials have provided support for the
preventive and therapeutic roles of Se in cancer development
(Wadhwani et al., 2017; Yang et al., 2017; Cui et al., 2018;
Zhang et al., 2018). Se is toxic to cancer cells due to a
correlated action between its pro-oxidant activity and its ability
to generate reactive oxygen species (ROS), which leads to
apoptosis (Gandin et al., 2018). Its specificity is conferred by
its enhanced uptake and accumulation in cancer cells compared
to normal somatic cells (Ruberte et al., 2020). While the reason
for this is not completely understood, one of the possible
mechanisms is the more reductive environment of the cancer
cells, which stimulates the formation of Se–S adducts from
Se compounds (Olm et al., 2009). As reported before, Se–S
adducts could simulate cystine and mixed disulfides, causing
enhanced receptor-mediated uptake of Se in cancer cells (Banjac
et al., 2008; Olm et al., 2009; Mandal et al., 2010; Ikram et al.,
2021).
It has been reported that SeNPs exhibit higher anticancer
efficacy and fewer side effects compared to inorganic and
organic selenium-containing molecular compounds (Yu
et al., 2012). This has led to the evaluation of SeNPs as
carriers of chemotherapeutics such as cisplatin (Li et al.,
2013), 5-fluorouracil (Liu et al., 2012), doxorubicin (Huang
et al., 2013; Zhou et al., 2017), and irinotecan (Gao et al.,
2014). These evaluative studies showed the synergistic effect
Abbreviations: Se, selenium; CS, chitosan; NPs, nanoparticles; NCs,
nanocomplexes; SeNPs, selenium nanoparticles; LBL-Se-NCs, layer-by-layer
selenium nanocomplexes; CS-NCs, chitosan nanocomplexes.
between the anticancer drugs and selenium, which selectively
induced apoptosis.
Apart from the delivery of small molecular drugs, recent
studies have confirmed the same synergistic effect of SeNPs in
combination with siRNA for targeted gene silencing as well (Li
et al., 2016; Chen et al., 2017; Xia et al., 2018a,b, 2020c). siRNA
is a synthetic double-stranded RNA that is able to interfere with
the expression of specific genes by cleaving the messenger RNA
(mRNA). This process is intracellularly mediated by the RNA-
induced silencing complex (RISC) (Matzke and Birchler, 2005).
siRNA-mediated gene silencing with SeNPs has been investigated
for the inactivation of MDR-associated genes (Zheng et al., 2016),
HSP70 (Li et al., 2016), and VEGF (Yu et al., 2014). However,
the Se delivery systems explored so far presented limitations in
terms of the formulation stability and the protection of siRNA.
Therefore, the need remains for improvements in the design of
Se-based nanocarriers in order to have a more stable formulation
while at the same time protecting the siRNA until it reaches the
cytosol where it can perform its therapeutic function (Yu et al.,
2014; Li et al., 2016; Maiyo and Singh, 2020).
Stability and endosomal escape efficiency of drug delivery
systems are directly linked to their physicochemical properties
(Lück et al., 1998; Gessner et al., 2002; Thorek and Tsourkas,
2008; Wang et al., 2021), which can be modulated by the
use of capping agents (Zhang et al., 2004; Song et al.,
2020b). The selection of appropriate capping agents to stabilize
SeNPs is regarded as a key requirement for their practical
application because aggregation results in a decrease in their
bioactivity and bioavailability (Zhang et al., 2012; Zheng et al.,
2015). Polysaccharides have been widely used as SeNP capping
agents because of their biocompatibility, low toxicity, and
biodegradability (Zhang et al., 2004; Yu et al., 2012). In
that sense, chitosan (CS), which is composed of randomly
distributed β-(1→4)-linked D-glucosamine (deacetylated unit)
and N-acetyl-D-glucosamine (acetylated unit) (Chen and Park,
2003; Kumar et al., 2004), is one of the most widely used
naturally biocompatible and biodegradable polysaccharides. Due
to its cationic nature, using CS as a capping agent should allow
for the electrostatic attachment of negatively charged siRNA
molecules to their surfaces (Han et al., 2012; Ahmad et al., 2021;
Shaabani et al., 2021).
In the present study, we used a straightforward layer-by-layer
self-assembly approach to synthesize stable Se-based siRNA-
loaded nanocomplexes (NCs). SeNPs are first capped with
chitosan during their synthesis to obtain Se@CS nanoparticles
with excellent colloidal stability. Next, siRNA is electrostatically
attached in the second step, forming Se@CS:siRNA nanoparticles.
In the final step, the final layer of chitosan is applied
(Se@CS:siRNA:CS) to provide protection to the siRNA and to
create a net cationic surface charge for better cellular uptake
(Scheme 1). These layer-by-layer Se nanocomplexes (LBL Se-
NCs) were characterized in terms of their size, surface charge,
stability, siRNA-binding capacity, and siRNA release profile.
Next, their in vitro uptake, cytotoxicity, and apoptotic effect
on H1299 lung carcinoma cancer cells were investigated in
comparison to siRNA-loaded nanocomplexes prepared from
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chitosan alone (CS-NCs). The selective anticancer effect of
LBL-Se-NCs was investigated by including NIH/3T3 fibroblasts
in the study as a normal cell line, similar to previous reports
(Ye et al., 2017). Overall, it was found that LBL-Se-NCs have
good colloidal stability and provide protection to siRNA while
being able to selectively induce apoptosis and siRNA gene
silencing in cancer cells. As such, this study is an important




Na2SeO3 and chitosan (low molecular weight, degree of
deacetylation: 80%) were purchased from Sigma-Aldrich
(St. Louis, MO, United States). RPMI-1640, L-glutamine,
Penicillin/Streptomycin solution (5,000 IU/ml penicillin and
5,000 µg/ml streptomycin) (P/S), Fetal Bovine Serum (FBS),
Trypan Blue, 0.25% Trypsin-Ethylenediaminetetraacetic acid
(EDTA), and Dulbecco’s phosphate-buffered saline (DPBS) were
supplied by Gibco BRL (Merelbeke, Belgium). CellTiter-Glo R©
Luminescent Cell Viability Assay was purchased from Promega
(Leiden, Netherlands). Hoechst 33342 was purchased from
Molecular Probes (Erembodegem, Belgium). Lipofectamine
RNAiMAX reagent was purchased from Invitrogen (Carlsbad,
CA, United States). jetPEI (jetPRIME R©) was purchased from
Polyplus-transfection R© company (France).
Small interfering RNA against eGFP (sieGFP, sense strand:
5′-CAAGCUGACCCUGAAGUUCtt-3′; antisense strand: GAACU
UCAGGGUCAGCUUGtt-3′) and non-targeted siRNA (siCTRL,
sense strand: 5′-CAAGCUGACCCUGAAGUUCtt-3′; antisense
strand: 5′-GAACUUCAGGGUCAGCUUGtt-3′) were purchased
from Eurogentec (Seraing, Belgium). For the uptake experiments,
the siCTRL duplex was labeled with Alexa Fluor 647 dye at
the 5′ end of the sense strand (si-AF647) (Eurogentec). For
the endosomal escape, red-labeled fluorescent oligonucleotides
(AF647 ONs) were used (Eurogentec).
In this study, we used H1299 and NIH/3T3 cells with a passage
number below 20. The number of cells was 7,500 cells/ml and
9,000 cells/ml for the 24 and 48 h studies, respectively.
Preparation of NCs
Core Nanoparticle Synthesis: Se@CS
Se@CS
Se nanoparticles stabilized with chitosan were prepared as
previously reported with minor modifications (Boroumand et al.,
2019). Briefly, 4 ml of 200 mM vitamin C (ascorbic acid) solution
was added drop-wise into 5.83 mg Na2SeO3 dissolved in 40 ml
of 0.2% (w/v) chitosan solution under magnetic stirring at 900
RPM for half an hour at room temperature. The stabilized Se@CS
nanoparticles were centrifuged at 21,000 g for 60 min allowing
the collection of the Se@CS NPs while removing the remaining
excess materials. The collected NPs were dispersed in RNase-
free water. UV-Visible, dynamic light scattering (DLS)/Zeta
potential, and Fourier transform infrared spectroscopy (FTIR)
characterization were performed to confirm the synthesis of the
core nanoparticles (Se@CS).
Layer-by-Layer Selenium Nanocomplex Synthesis:
LBL-Se-NCs
The LBL-Se-NCs are composed of three layers: the core (Se@CS),
a second layer with the siRNA (Se@CS:siRNA), and a third
protective chitosan layer (Se@CS:siRNA:CS). These LBL-Se-NCs
were synthesized in two steps, given as follows:
Se@CS:siRNA
Surface loading of siRNA was carried on different weight ratios
of siRNA to Se from 1:2.5 to 1:40 (w/w) under constant stirring at
400 RPM for 60 min.
Se@CS:siRNA:CS
Finally, after 60 min, the third layer was applied by adding a 0.5%
(w/v) chitosan solution to the reaction under continuous stirring
for another 60 min. The resulting NCs were centrifuged again
at 21,000 g/min for 60 min to remove all unreacted materials,
after which the collected precipitate was resuspended in RNase-
free water.
CS-NCs
In this study, chitosan is the most determining part with regard
to siRNA complexation, cellular uptake, and endosomal release;
so, we consider CS-NCs as a suitable control group to compare
with the Se@CS:siRNA:CS group. In this regard, siRNA-chitosan
nanocomplexes were prepared by the ionic gelation method,
reported in a prior study, with some modifications (Katas
and Alpar, 2006). CS-NCs were prepared by adding siRNA in
double-distilled water to the tripolyphosphate (TPP) solution
(1.2 ml, 1 mg/ml) before adding this drop-wise to the chitosan
solution (3 ml, 2 mg/ml) under constant magnetic stirring at
room temperature. The particles were then incubated at room
temperature for another 30 min before centrifugation at 21,000 g
at a temperature of 4◦C.
Characterization of NCs
Hydrodynamic diameter and surface charge of LBL-Se-NCs were
determined using a Zetasizer Nano (Malvern, Worcestershire,
United Kingdom) in each step of the synthesis.
The molecular structure of the core nanoparticles (Se@CS)
was analyzed using FTIR by mixing the core nanoparticles with
KBr (1:50, w/w) and pressing them into uniform pellets to
perform scanning in the wavenumber range 4,000–400 cm−1.
Transmission electron microscopy (TEM) images were
obtained at the VIB-UGent Transmission Electron Microscopy-
Core facility using a JEM 1400 plus transmission electron
microscope (JEOL, Tokyo, Japan) operating at 80 kV. Samples
were prepared for the TEM analysis by adding 50 µl of
the nanoparticle dispersions on formvar/C-coated hexagonal
copper grids (EMS G200H-Cu). After 20 min of waiting at
room temperature, they were washed with double-distilled
water several times.
The entrapment of siRNA in NCs was assessed by a NanoDrop
2000c spectrophotometer (Thermo Scientific, Rockford, IL,
United States). To determine the amount of free siRNA
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SCHEME 1 | Schematic illustration of layer-by-layer selenium nanocomplexes (LBL-Se-NCs). LBL-Se-NCs are composed of three layers: the core (Se@CS), a
second layer with the cargo (siRNA), and a third protective layer of chitosan (CS). The nanocomplexes are taken up by cancer cells via endocytosis and trafficked via
endosomes before finally escaping from endolysosomes. The released eGFP-siRNA and Se will induce a dual effect of apoptosis on the one hand and knockdown of
the target protein on the other hand.
in the supernatant recovered after particle centrifugation
(21,000 × g, 60 min), the typical absorbance of nucleic acids at
260 nm was monitored. siRNA entrapment in NCs was further
confirmed by agarose gel electrophoresis. A 2% agarose gel was
prepared by dissolving agarose (UltraPure Agarose, Invitrogen,
Erembodegem, Belgium) in a 100 ml TBE buffer (98 mM Tris,
88 mM Boric acid, 2 mM Na2EDTA with pH 8). GelRed (Biotium,
Hayward, CA, United States) was added to the TBE buffer for
siRNA detection and 5 µl of 5 × Gel Loading Buffer (Ambion,
Merelbeke, Belgium) was added for every 20 µl of the sample
before running for 20 min at 120 V. A total volume of 20 µl
was pipetted per lane and a siRNA ladder was added as well
as a control. We used a Kodak digital science camera (Kodak
EDAS 120, Rochester, NY, United States) to take an image of
the gel under UV light (Bio-Rad UV Transilluminator 2000,
CA, United States).
Stability of NCs
The stability of the LBL-Se-NCs was determined after
resuspending and incubating NCs in different media (ddi.
water pH 7.4, DMEM [Dulbecco’s Modified Eagle’s Medium],
HEPES, PBS, acidic water [pH 3], and alkaline water [pH 9])
for 1 h and observing changes in the hydrodynamic diameter.
The stability of the NCs was also evaluated by monitoring
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changes in the hydrodynamic diameter and zeta potential in
RNase-free water at room temperature for both LBL-Se-NCs and
CS-NCs over 20 days.
siRNA Release From the NCs
The in vitro release study was carried out by determining the
released siRNA from LBL-Se-NCs and CS-NCs post-synthesis.
In this technique, we separated the release media from the
nanoparticles by centrifugation (Cetin et al., 2010; D’Souza,
2014). The released siRNA was quantified in the supernatant
using a NanoDrop at a wavelength of 260 nm. Briefly, LBL-
Se-NCs and CS-NCs were incubated in microtubes containing
10 mM HEPES buffer with a pH of 7.4 and gently shaken at
37◦C. At specific time points, the supernatant of the samples was
taken from one of the microtubes after centrifuging at 21,000 g
for 60 min, and the concentration of siRNA in the supernatant
was measured to determine the amount of released siRNA at each
time point during 7 days after synthesis.
Cytotoxicity Studies
H1299 cells (lung epithelial cells derived from metastatic
lymph nodes, ATCC-CCL 5803) stably expressing enhanced
green fluorescence protein (eGFP) were cultured in Roswell
Park Memorial Institute (RPMI) 1640 medium supplemented
with 10% FBS, 2 mM L-Glutamine, and 100 µg/ml P/S in
a humidified incubator at 37◦C with 5% CO2 atmosphere.
NIH/3T3 cells (embryo-derived fibroblast cells, ATCC-CRL-
1658) were cultured in DMEM supplemented with 10% Calf
serum, 2 mM L-Glutamine, and 100 µg/ml P/S in a humidified
incubator at 37◦C with 5% CO2 atmosphere. For all in vitro
studies, NCs, prepared at a 1:40 weight ratio of siRNA to Se,
were diluted in a culture medium to reach a final concentration
of 2–64 nM siRNA.
The cells were seeded in 96-well plates at 7,500 cells per well
(for 48 h study) and were allowed to attach overnight. On the
next day, the cells were treated with the prepared NCs (2–64 nM
siRNA concentration) for 4 h at 37◦C in cell culture medium.
Next, the cells were washed once with PBS and incubated in
a fresh cell medium for an additional 24 h before they were
prepared for measuring their metabolic activity by the CellTiter-
Glo R© assay. On the next day, after replacing the cell culture
medium with 100 µl of fresh medium, 100 µl of CellTiter-Glo R©
reagent was added in each well and mixed for 20 min on an
orbital shaker (Rotamax 120, Heidolph, Germany) to induce
cell lysis. The mix was further incubated at room temperature
for 10 min to let the luminescent signal stabilize. Next, 100 µl
suspension of each well was transferred to white 96-well plates
and the luminescence signal was recorded by a GloMax R© 96
Luminometer (Promega). Wells containing medium without cells
were included to determine the background luminescence.
DiIC1(5)/Propidium Iodide Apoptosis
Assay
Induction of apoptosis in NCs-treated H1299 and NIH/3T3 cells
was evaluated by flow cytometry using propidium iodide (PI) and
dihexaoxacarbocyanine iodide (DiIC1). The cells were seeded in
a 96 well culture plate and cultured for 24 h, after which they
were treated with different concentrations of LBL-Se-NCs and
CS-NCs (2–64 nM siRNA concentration) for 4 h at 37◦C in a
cell culture medium. Next, the cells were washed and incubated
for an additional 24 h. On the next day, the culture medium was
removed and transferred to another plate because the removed
medium could contain dead cells that should also be included
in the analysis. The cells were detached from the well plates
using trypsin and then neutralized after 5 min with the medium
that was kept from the previous step (and that may contain
additional dead cells). Following centrifugation (5 min, 500 g),
the cell pellet was resuspended in staining buffer prepared from
flow buffer (DPBS−, 0.1% Sodium Azide, 1% Bovine Serum
Albumin) to which PI (1 µg/ml) and DiIC1 (10 nM) were
added. The cells were incubated with the staining buffer for
30 min at 37◦C before being analyzed with flow cytometry
(CytoFLEX, Beckman Coulter, Krefeld, Germany). The FlowJo
software (Tree Star Inc., Ashland, OR, United States) was used
to separate the cell population into three parts: Q1: live cells (high
intensity of deep red fluorescence, DilC1(5)+/PI−); Q3: apoptotic
cells [no fluorescence, DilC1(5)−/PI−]; and Q4: dead cells [red
fluorescence, DilC1(5)−/PI+].
Evaluation of Uptake via Flow Cytometry
Uptake experiments were performed by seeding 9,000 H1299 and
NIH/3T3 cells per well in 96-well plates which were allowed to
attach overnight. The next day, NCs containing AF647 siRNA
were prepared as described above. The cells were incubated with
LBL-Se-NCs and CS-NCs (2–64 nM siRNA concentration) for 4 h
at 37◦C, after which they were washed and detached from the
well plates using trypsin, and then neutralized with a complete
cell culture medium. The cells were transferred to U-Bottom
96-well (Greiner Bio-One GmbH, Vilvoorde, Belgium) plates
and centrifuged (5 min, 500 g), after which the cell pellet was
resuspended in flow buffer for flow cytometry analysis.
For each sample, the forward and side scatter (FSC and SSC,
respectively) were measured for 60 s at a flow rate of 60 µl/min.
Red fluorescence (excitation at 638 nm and detection with a
660/20 nm bandpass filter) was measured using a CytoFLEX flow
cytometer. Finally, data analysis was performed using the FlowJo
software for quantifying the percentage of positive cells (uptake
[%]) as well as the relative mean fluorescence intensity per cell
(rMFI) according to:
rMFI(relative Mean Fluorescence Intensity)
=
MFI of cells treated with Alexa Fluor 647siRNA
MFI of cells treated with nonlabeled siRNA
Evaluation of Transfection Efficiency via
Flow Cytometry
For calculating the siRNA gene silencing efficiency on eGFP-
H1299 cells, 7,500 cells per well were seeded (for 48 h study)
in 96-well plates which were allowed to attach overnight. On
the next day, the cells were treated with NCs containing eGFP-
siRNA (sieGFP) and negative control-siRNA (siCTRL) (2–64 nM
siRNA concentration) for 4 h at 37◦C in RPMI. Next, the cells
were washed and incubated for an additional 24 h. On the next
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day, following the same steps previously mentioned for flow
cytometry, the cells were washed, detached, centrifuged, and
resuspended in flow buffer for flow cytometry analysis. For each
sample, the forward and side scatter (FSC and SSC, respectively)
were measured for 60 s at a flow rate of 60 µl/min. The samples
were excited with a 488 nm laser line and the signal was detected
with a 525/40 filter using a CytoFLEX plate reader flow cytometer.
The FlowJo software was used to measure eGFP expression
according to the following equation:




MFI siGFP indicates the mean fluorescence intensity of cells
treated with GFP-siRNA and MFI siCTRL indicates the mean
fluorescence intensity of cells treated with negative control-
siRNA.
The eGFP knockdown efficacy was also evaluated by taking
microscopy images after treatment with a Nikon A1R HD
confocal laser scanning microscope (Nikon Benelux, Brussels,
Belgium), equipped with a laser box (LU-N4 LASER UNIT
405/488/561/640, Nikon Benelux, Brussels Belgium), detector
box (A1-DUG-2 GaAsP Multi-Detector Unit, GaAsp PMT for
488 and 561 and Multi-Alkali PMT for 647 and 405 nm), and
a 20X air objective lens (CFI plan Apo VC 20X, NA 0.75, WD
1,000 µm) (Nikon, Japan). The images were recorded using
the NIS Elements software (Nikon, Japan). Briefly, H1299-eGFP
cells were seeded in 35 mm CELLview microscopy dishes with
glass bottom (Greiner Bio-One, Vilvoorde, Belgium) at a density
of 75,000 cells per ml and were allowed to settle overnight.
After removal of cell culture medium, the cells were treated for
4 h with LBL-Se-NCs, jetPEI, Lipofectamine, and CS-NCs, all
containing 8 nM eGFP-siRNA and 8 nM naked eGFP-siRNA
as a carrier-free control. Live-cell imaging was performed for
evaluating knockdown efficacy after 24 h of treatment at 37◦C.
Before confocal imaging, the cells were washed and stained with
Hoechst 33342 (1 mg/ml in H2O; 1,000 × diluted). After 20 min
of incubation with Hoechst, the cells were washed three times
with PBS. The stained cells were provided with a full cell culture
medium and put on the microscope with an incubator to enable
live-cell imaging at optimal environmental conditions (5% CO2,
100% humidity, and 37◦C). The 408 and 488 nm laser lines
were used to excite the Hoechst-labeled nuclei and the eGFP
protein, respectively.
Visualization and Quantification of
Endosomal Escape
Endosomal escape was evaluated by a dequenching assay first
published by Rehman et al. (2013). For this, LBL-Se-NCs, jetPEI,
Lipofectamine, and CS-NCs containing 8 nM AF647 ONs (red-
labeled fluorescent oligonucleotides) were prepared and added to
cells (75,000 cells per ml seeded in 35 mm CELLview microscopy
dishes [Greiner Bio-One, Vilvoorde, Belgium]) for 4 h at 37◦C,
after which they were washed and incubated overnight at 37◦C
and 5% CO2. After 24 h, the cell nuclei were stained with Hoechst
33342 (1 mg/ml in H2O; 1000 × diluted) and incubated for
20 min 37◦C and 5% CO2. Immediately after washing, the cells
were provided with a full cell culture medium and were placed
in the incubator of the microscope (37◦C under a humidified 5%
CO2 atmosphere).
For visualization, the 408, 488, and 633 nm laser lines were
applied to excite the Hoechst-labeled nuclei, eGFP protein, and
the AF647 ONs, respectively. Upon endosomal escape, free
AF647 ONs would be released into the cytosol and accumulate
into the nucleus. Data analysis with the ImageJ (FIJI) (Schindelin
et al., 2012) software was performed to determine both the total
number of cells and the number of cells with AF647 ON-positive
nuclei. The ratios of both give the percentage of cells in which
at least one endosomal escape event has happened. The nuclei
were detected in the blue channel by thresholding (applying the
same offset values for every image), and intensity analysis of the
nuclear fluorescence signal in the red channel was performed. At
least 250 cells in a minimum of 25 images were included for all
conditions tested.
Statistical Analysis
All statistical analyses were performed using the GraphPad
software (La Jolla, CA, United States), and the propagation of
errors was applied when necessary. One-way ANOVA or the
Student’s t-test was used for comparing conditions. All results
are reported as mean± SD and differences with a p-value < 0.05
considered significant.
RESULTS
Core (Se@CS) Nanoparticle Synthesis
and Characterization
The main goal of this study is the design and synthesis of
novel layer-by-layer Se-based nanocomplexes (LBL-Se-NCs) for
siRNA delivery in synergy with the native anticancer properties
of selenium. For this, we started by synthesizing core SeNPs
using chitosan as a coating (Se@CS). TEM imaging confirmed
the formation of Se nanoparticles with a size of 74.3 ± 5 nm
(Figure 1A). The hydrodynamic diameter of the Se@CS core
nanoparticles was measured in ddi. water as well, showing an
average diameter of 218 ± 3 nm with PDI = 0.24 and a positive
Zeta potential of 52 ± 0.1 mV which suggested that the chitosan
was successfully capped on the surface of the nanoparticle
(Figures 1C,D, ‘first layer’). The hydrodynamic size as measured
by DLS being larger than what is measured by TEM is likely
due to the fact that in DLS, the polymer coating of the particle
is fully hydrated, while the samples are dehydrated for TEM
imaging. To further prove the presence of a chitosan coating, the
Se@CS nanoparticles were additionally analyzed by FTIR. The
spectrum shown in Supplementary Figure 1A has clear features
at 3,300–3,500 cm−1 which correspond to the vibrational modes
of chitosan, in particular, stretching vibrations of O-H and N-H.
Compared to the spectrum of chitosan alone, there is a slight blue
shift due to the formation of hydrogen bonds between selenium
and chitosan (Song et al., 2020a,b). Other clear characteristic
bands of chitosan can be seen at 1,664 (amide I), 1,548 (amide
II), and 1,407cm−1 (amide III). The peak located at 1,150 cm−1
is the result of chitosan deacetylation and is related to asymmetric
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FIGURE 1 | Synthesis of LBL-Se-NCs. (A) TEM images of Se@CS nanoparticles. The images confirmed the formation of SeNPs and indicate an average particle
size of around 74.3 ± 5 nm. (B) The siRNA-loading capacity of Se@CS nanoparticles, from 1:2.5 to 1:40 siRNA:core mass ratios, was evaluated by measuring the
remaining siRNA content in the supernatant by agarose gel electrophoresis. (C,D) The hydrodynamic diameter (C) and the surface charge (D) of the nanoparticles
were evaluated with dynamic light scattering after each step in the synthesis process. The first layer corresponds to Se@CS, the second layer to Se@CS:siRNA, and
the third layer to Se@CS:siRNA:CS. (n = 3). (E) UV-Visible spectra of the different stages of the LBL synthesis of Se-NCs. (F) TEM images of Se@CS:siRNA (G) and
Se@CS:siRNA:CS. (H) TEM images of CS-NCs.
vibrations of CO in the oxygen bridge. The absorption bands
at 1,082 and 1,032 cm−1 (skeletal vibrations involving the
C-O stretching) are characteristic of its saccharide structure
(Silva et al., 2012; Yu et al., 2012; Song et al., 2020b). These
vibrational modes present in the FTIR spectra further confirmed
the presence of CS on the surface of the core nanoparticles.
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Formation and Characterization of
LBL-Se-NCs
The next step was to load siRNA on the Se@CS nanoparticles.
siRNA was added at different weight ratios of siRNA to Se from
1:2.5 to 1:40 (w/w). After the addition of siRNA to the Se@CS core
particles, the dispersion was centrifuged to remove any unbound
siRNA. The presence of unbound siRNA in the supernatant
was investigated by UV-Vis spectroscopy and agarose gel
electrophoresis in order to determine the siRNA-loading capacity
of the Se@CS core nanoparticles. When performing agarose gel
electrophoresis on the supernatant, it was found that siRNA
was fully complexed to the core nanoparticles at a ratio of
1:40, corresponding to an effective siRNA concentration of
160 nM (Figure 1B). At higher ratios, an increasing amount
of unbound siRNA was detected in the supernatant. This was
further confirmed by the UV-Vis spectra of the supernatant
(Supplementary Figure 1B), which showed a gradual increase in
unbound siRNA as the ratio increased.
Based on these results, LBL-Se-NCs at a ratio of 1:40 (w/w)
with an effective siRNA concentration of 160 nM were selected
for further characterization. Upon coating with anionic siRNA,
the positive surface charge of Se@CS decreased as expected,
reaching a value of 35.0 ± 1.5 mV. At the same time, a decrease
in the hydrodynamic diameter was observed from 218 ± 3 nm
(Se@CS) to 174 ± 1.2 nm (Se@Cs:siRNA) (Figures 1C,D). The
reason for this decrease can be related to the condensation state of
the polymer by the incorporation of small and highly negatively
charged molecules in the macromolecular organization of the
LBL structure (siRNA). Finally, the last protective chitosan layer
was applied, thus obtaining Se@CS:siRNA:CS nanocomplexes,
whose zeta potential increased again to 44 ± 3 mV, with a size
of 237.0± 0.8 nm (Figures 1C,D).
The process of layer coating on the core was also monitored
by UV-Vis spectroscopy. As shown in Figure 1E the synthesized
Se@CS had a band with a maximum of about 260 nm. However,
after the deposition of siRNA on the core surface to form
Se@CS:siRNA, the intensity of the band increased, indicating the
formation of the siRNA layer. In addition, after the formation
of the third layer with chitosan, an increase of around 200 nm
at the extinction spectrum was observed, which is related to the
attached chitosan on the surface.
We performed additional experiments in which the stability of
Se@CS:siRNA nanocomplexes was examined after purification by
centrifugation before and after applying the third chitosan layer.
Analysis by DLS and simple visual inspection clearly showed that
the presence of the third layer has an effect on the resuspension
of the NCs in water. For nanocomplexes without the third layer,
we could observe flocculation and sedimentation, while DLS also
showed that the overall size of the NCs had increased with clear
signs of aggregation (Supplementary Figures 1C,D).
The TEM images were also recorded after the second
(Se@CS:siRNA) and the third step (Se@CS:siRNA:CS). The
addition of the second siRNA (Figure 1F) did not change the
morphology or size with sizes of 74 ± 5 and 73 ± 8 nm for
the core post-synthesis and for the complexes after attachment
of the siRNA (second layer), respectively. Despite observing a
reduction in size after the attachment of the second layer in the
DLS study, this change in size was not visible in the microscopic
images. The reason why this difference is better detectable by
DLS could be the expansion of the polymer coating in the
aqueous phase during DLS measurements, while TEM imaging is
performed on dehydrated samples. Also, similar changes in size
are reported in the study by Maiyo and Singh (2020) in which,
after the addition of siRNA on CS-covered Se nanoparticles,
the nanocomplexes had slightly reduced diameters compared to
uncomplexed nanoparticles.
On the other hand, the final chitosan layer was visible in
the TEM images as a faint ‘halo,’ which resulted in an effective
increase of the overall size of the nanoparticle to 95 ± 11 nm
(Figure 1G). Figure 1H is TEM image of CS-NCs, and as can be
seen, their solidarity is less than LBL-Se-NCs.
Evaluation of Stability of LBL-Se-NCs
and siRNA Release Profile
One of the first challenges for a drug delivery system is achieving
good colloidal stability and not preventing aggregation (Buyens
et al., 2008, 2012; Raemdonck et al., 2013). Therefore, we
first evaluated the stability of LBL-Se-NCs in different media,
including ddi. water (pH 7.4, 3, 9), HEPES buffer, DMEM,
and PBS. To judge the role of the Se core, a comparison
was performed with nanocomplexes prepared from CS-NCs.
Figure 2A shows the hydrodynamic size of both LBL-Se-NCs
and CS-NCs after 1 h of incubation in the different media. It is
immediately clear that the LBL-Se-NCs have superior colloidal
stability compared to CS-NCs irrespective of the suspension
medium. The size and zeta potential of both nanoparticles were
monitored post-synthesis in RNase-free water for up to 480 h
(20 days). While the size of LBL-Se-NCs started to increase
slightly after 10 days due to a gradual drop in the zeta potential,
their colloidal stability was markedly better than that for CS-NCs,
which started to aggregate just after 2 days (Figure 2B).
Next, the siRNA release from LBL-Se-NCs and CS-NCs was
monitored over time for a period of 7 days (Figure 2C). LBL-Se-
NCs and CS-NCs were stored in microtubes containing 10 mM
HEPES buffer (pH 7.4) and were continuously gently shaken at
37◦C. At specific time points, samples were taken and centrifuged
at 21,000 g for 60 min to determine the amount of released
siRNA in the supernatant. In the case of CS-NCs, more than
50% siRNA was already released after only 8 h, reaching 100%
release after just 48 h. In contrast, the siRNA release from LBL-
Se-NCs was only 35% after 7 days. These results show that, under
equal experimental conditions, siRNA remains better associated
to LBL-Se-NCs as compared to CS-NCs.
In vitro Anticancer Activity: Cell Viability
and Apoptosis Assays
To determine the selective anticancer potential of LBL-Se-NCs,
LBL-Se-NCs and CS-NCs were added to H1299 (cancer cells)
and NIH/3T3 (normal cells) at concentrations ranging from 2 to
64 nM of siRNA, corresponding to 1–32 ppm of selenium. Note
that untargeted siRNA was used in these experiments so as to
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FIGURE 2 | Evaluation of LBL-Se-NC colloidal stability and siRNA release.
Characterization of LBL-Se-NCs and CS-NC (A) colloidal stability in different
media: ddi. water (pH 7.4, 3, 9), DMEM, HEPES, PBS. (B) Colloidal stability as
a function of time in RNase-free water as measured by DLS and zeta
potential. (C) siRNA release profile from LBL-Se-NCs and CS-NCs as a
function of time. Bars represent mean ± SEM, for a minimum of three
independent experiments.
judge the anticancer effect by the carriers alone. The CellTiter-
Glo metabolic assay was used to quantify cell viability after 24 h.
As shown in Figure 3A, LBL-Se-NCs effectively suppressed the
growth of H1299 cells in a dose-dependent manner. About 50%
loss in cell viability was observed at a siRNA concentration of
8 nM (4 ppm of Se) on H1299 cells, while the cell viability of
NIH/3T3 normal cells was still∼100% at the same concentration.
At the highest concentration of 64 nM (32 ppm of Se), almost
all H1299 cancer cells had died, while the viability of NIH/3T3
cells remained > 50%. When CS-NCs were applied to the
cancer cells in the same concentration range, no clear difference
in cell viability between H1299 and NIH/T3T cells could be
observed, with the cell viability remaining > 80% even at the
highest concentration.
Next, we proceeded to evaluate the induction of apoptosis on
both cell lines. One of the methods that allow for distinguishing
apoptotic cells from necrotic cells is the combination of two
dyes: DiIC1(5) fluorochrome and PI. DiIC1(5) (λex 638 nm; λem
658 nm) is a deep red, lipophilic dye that is selective for the
mitochondria of live cells, causing high fluorescence intensity;
meanwhile, for apoptotic cells, when the membrane potential of
the mitochondria is no longer intact, the dye diffuses over the
cytoplasm and the staining is less intense. PI (λex 482 nm; λem
608 nm), cannot cross intact plasma membrane and therefore will
only be present in the DNA of necrotic cells where the plasma
membrane has been compromised/permeabilized. Therefore, the
combination of these two dyes allows for distinguishing apoptotic
from necrotic cells by flow cytometry. Treatment with LBL-Se-
NCs at a concentration of 8 nM resulted in 32.0 ± 0.7% and
5.6 ± 0.8% apoptosis in H1299 and NIH/3T3 cells, respectively
(Figure 3B). This means a 5.7-times higher selective apoptosis
induction for the LBL-Se-NCs in cancer cells in comparison
to normal cells. CS-NCs, on the other hand, had low levels of
apoptosis induction in both cell lines (H1299 and NIH/3T3 cells)
with no clear difference. As the CS-NCs control group includes
all the substances in the LBL-Se-NCs except for the Se core,
this result shows that the apoptosis effect indeed arises from the
presence of the Se core. Furthermore, an obvious increase in the
necrotic population could be seen in none of the treated cells,
pointing to an absence of acute toxicity by either of the carriers
(Supplementary Figure 2).
In vitro siRNA Delivery of NCs
To verify if the cell-selective effect of LBL-Se-NCs is due
to a difference in uptake, the nanocarriers were loaded with
fluorescently labeled AF647 siRNA for the quantification of
uptake via flow cytometry. Figure 3C shows that the percentage
of cells positive for AF647 siRNA (uptake%) was indeed
markedly higher for H1299 cells as compared to NIH/3T3
cells. The difference was even more pronounced when looking
at the rMFI values, which are a measure for the amount of
uptake per cell (Figure 3D). Together, these details point to a
direct correlation between the amount of internalized NCs and
apoptosis induction. Surprisingly, the percentage of positive cells
was quite similar for both cell types when comparing CS-NCs
with LBL-Se-NCs, which, at first glance, would suggest an equal
amount of internalization. However, the much lower rMFI values
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FIGURE 3 | Comparison of biological effect by LBL-Se-NCs and CS-NCs in H1299 and NIH/3T3 cells. (A) Cell viability after treatment of H1299 (cancer cells) and
NIH/3T3 (normal cells) with LBL-Se-NCs and CS-NCs. (B) Flow cytometric determination of apoptotic and necrotic populations of cells treated with LBL-Se-NCs in
comparison with CS-NCs on H1299 and NIH/3T3 cells. (C) Uptake of AF647 siRNA-loaded Se-NCs and CS-NCs in H1299 and NIH/3T3 cell lines quantified via flow
cytometry. ‘Uptake%’ refers to the percentage of cells that are positive for AF647. (D) The corresponding relative mean AF647 fluorescence intensity per cell (rMFI),
which is proportional to the amount of particles that are taken up per cell on average. Bars represent mean ± SEM (n = 3, *p < 0.05; **p < 0.01; ***p < 0.001).
show that this is not the case, with fairly little uptake in either
of the cell lines.
In vitro Transfection Efficiency of NCs
Next, we proceeded to evaluate the ability of LBL-Se-NCs to
functionally deliver siRNA into cancer cells. To this end, the
transfection performance was evaluated with nanocarriers loaded
with anti-eGFP siRNA in concentrations from 2 to 64 nM
(Figure 4A). Briefly, H1299-eGFP cells were incubated with
LBL-Se-NCs for 4 h, washed, and kept in fresh cell culture
medium for an additional 24 h before eGFP knockdown with
flow cytometry. The flow cytometry analysis showed that, for
an effective siRNA concentration of 8 nM, the eGFP expression
was reduced by ∼35%. While the eGFP expression did not
reduce further at higher concentrations, cell viability did, which
goes hand in hand with an increased amount of internalized
nanocarriers (Figure 3A). To better appreciate the extent of the
knockdown, we additionally performed a comparison with CS-
NCs and popular commercial transfection reagents like jetPEI
and Lipofectamine. Naked eGFP-siRNA was added as a control.
As can be seen from the flow cytometry results in Figure 4B,
and supported by the confocal images in Figure 4C, at the same
effective siRNA concentration of 8 nM, no significant differences
between LBL-Se-NCs and other carriers in terms of knockdown
efficiency were observed. As expected, there was no measurable
effect of the naked eGFP-siRNA. Since long-term stability and
effectivity is an important consideration as well when designing
nanoformulations for drug delivery, we also measured the knock-
down efficiency 7 days after the various nanocomplexes were
synthesized (Figure 4B). LBL-Se-NCs showed the same result as
when they were freshly synthesized. This was, however, not the
case for any of the other (commercial) carriers, which, apart from
Lipofectamine, had completely lost their efficacy after 7 days.
Evaluation of Endosomal Escape
In order to get a deeper understanding of the experimentally
observed downregulation efficiencies for eGFP, we proceeded
to evaluate endosomal escape efficiencies based on a previously
published fluorescence microscopy assay (Rehman et al., 2013;
Vermeulen et al., 2018). Briefly, NCs were prepared with red-
labeled fluorescent oligonucleotides (AF647 ONs) instead of
siRNA. When incorporated into the NCs, the fluorescence of
the ONs is mostly quenched. But upon endosomal escape, the
labeled ONs would spread toward the cytoplasm, dequench, and
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FIGURE 4 | In vitro knockdown efficiency of LBL-Se-NCs. (A) GFP expression (%) of H1299 cells treated with LBL-Se-NCs as a function of siRNA concentration.
(B) Comparison of the GFP expression level on H1299 cells after treatment with LBL-Se-NCs, Lipofectamine, jetPEI, CS-NCs, and naked siRNA, all at 8 nM effective
siRNA concentration, for both freshly synthesized and 7-day-old nanocomplexes. (C) Confocal images of intracellular GFP knockdown of LBL-Se-NCs and control
groups on H1299 cells. The scale bar corresponds to 50 µm. Data are presented as mean values ± SD (n = 3, *p < 0.05; **p < 0.01; ***p < 0.001).
the free ONs would accumulate into the nucleus (Figure 5C). As
shown in the confocal images in Figure 5A, the accumulation of
free ONs in the nucleus was detected in several cells, indicating
that endosomal escape events had occurred for all tested NCs
but not for free AF647 ONs. The histograms in Figure 5B
show the red fluorescence intensity of the cell nuclei for the
respective NCs as determined from the confocal images. By
counting the total number of nuclei in confocal images on
the one hand (by Hoechst staining) and red fluorescent nuclei
on the other, the percentage of cells in which at least one
endosomal escape event has occurred can be calculated. The
cells that exhibited endosomal escape amounted to 43, 57, 42,
and 52% for LBL-Se-NCs, Lipofectamine, jetPEI, and CS-NCs,
respectively (Figure 5D). These results correlate very well to the
GFP transfection efficiencies, showing that endosomal escape is





In cancer nanomedicine, nanocarriers usually do not play a role
in the anticancer process and only act as a vehicle to deliver their
therapeutic content (Rosenblum et al., 2018). However, recent
studies have shown that Se-based carriers can play a role in
inhibiting cancer growth (Weekley and Harris, 2013). Relentless
cell division and proliferation of cancer cells, combined with their
aberrant metabolism, lead to an increased oxidized environment
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FIGURE 5 | Evaluation of Endosomal Escape based on AF647 ONs. (A) Representative confocal images 24 h post-incubation with AF647 ONs-loaded NCs in
eGFP-H1299 cells. Upon endosomal escape, the labeled ONs which are loaded into the various nanocomplexes spread toward the cytoplasm, dequench, and
finally accumulate into the nucleus. Hoechst nuclei can be seen in blue, while cells in which the endosomal escape occurred show nuclear fluorescence in the red
channel (white arrows). The scale bar corresponds to 50 µm. (B) The histogram of red fluorescent intensity of cell nuclei. (C) Scheme of ONs uptake, endosomal
escape, and accumulation in the nucleus. (D) The percentage of cells that had at least one endosomal escape event as quantified from AF647 fluorescence of at
least 250 nuclei. The scale bar corresponds to 50 µm, (n = 3, *p < 0.05; **p < 0.01; ***p < 0.001).
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(Cairns et al., 2011). Therefore, to evade ROS-induced cell death,
cancer cells have an aberrant metabolism that promotes some
agents to scavenge ROS and repair ROS-induced damage with
molecules like glutathione peroxidase, glutathione-S-transferase,
glutaredoxin, thioredoxin, superoxide dismutase, and catalase
(Glorieux and Calderon, 2017). This leaves the cancer cells with
very little or no room to accommodate any further increase in
ROS levels. Indeed, even a slight increase in ROS levels can lead
to apoptosis-dependent cell death in the cancer cells (Cairns
et al., 2011). This is not the case for normal healthy cells, which
can still cope with increased ROS levels via the upregulation of
antioxidant systems. On the other hand, this oxidative stress and
redox imbalance in cancer cells will stimulate the formation of
Se–S adducts from Se compounds and, subsequently, will increase
receptor-mediated uptake of Se in cancer cells, in contrast to
normal cells (Olm et al., 2009; Mandal et al., 2010). Hence,
ROS induction may selectively kill cancer cells without affecting
normal cells (Gorrini et al., 2013). Consequently, inducing
oxidative stress in cancer cells using redox modulators provides
an interesting therapeutic opportunity for cancer treatment
(Gandin et al., 2018). Se compounds have been well documented
to act as redox modulators and have shown higher selectivity
and sensitivity in apoptosis induction in the malignant cells
(Valdiglesias et al., 2010; Chaiswing et al., 2018). In this regard,
approaches based on Se nanocarriers have shown promising anti-
proliferation activity and inhibition of cancer cells, exhibiting
different effects in malignant vs. normal cells. Moreover, the use
of SeNPs conjugated with siRNAs has shown great promise in
many types of cancer research (Zheng et al., 2015; Li et al., 2016).
Despite these demonstrated advantages, the application of Se-
based carriers for gene delivery remains hindered due to poor
stability (Yu et al., 2014; Li et al., 2016; Xia et al., 2020a,b).
The exact anticancer mechanisms of SeNPs for the formulation
presented in this study still need to be explored. Nevertheless, it
is well documented that the anticancer properties of Se are related
to the induction of apoptosis (Huang et al., 2013; Liao et al., 2015;
Tian et al., 2020). In this study, we proposed to take advantage of
these properties and set out to develop a novel Se-based siRNA
delivery system that combines the benefits of Se-based carriers
with improved colloidal stability while still providing efficient
siRNA transfections.
We designed a layer-by-layer strategy to coat Se@CS in such a
way that the core confers a solid anchoring nucleus around which
the layer-by-layer system is built. By using UV-Vis spectroscopy
and agarose gel electrophoresis, the ability of chitosan to interact
with siRNA was confirmed. A third and final chitosan layer was
needed, however, to have a fully stable formulation that can
withstand aggregation during centrifugation washing steps. This
suggests that the surface charge in this system is an important
determinant of the stability of LBL-Se-NC. We would like to
note, however, that the nature of the third layer deposition
cannot be simply electrostatic due to the lack of net negative zeta
potential, but it is possible that local areas of high electron density
groups facilitate the attachment of the third layer of chitosan. The
increase in the size and positive surface charge after applying the
third layer definitely indicates that chitosan deposition has been
performed (Figures 1C,D). Furthermore, in Figure 1E, after the
formation of the third layer with chitosan, an increase of around
200 nm at the extinction spectrum was observed, which is related
to the attached chitosan on the surface. The final chitosan layer is
also visible in the TEM images as a faint ‘halo,’ which resulted
in an effective increase in the overall size of the nanoparticle
to 95 ± 11 nm (Figure 1G). How this interaction took place
even between positively charged macromolecules is a point that
seems to be related to the spatial and structural shape of the
polymers that were also reported in previous studies (Wu et al.,
2019). Importantly, we found that the presence of a Se resulted
in markedly enhanced stability over time, showing no variation
in size and zeta for at least 20 days (Figure 2). Instead, carriers
made from CS alone started to aggregate just after 48 h.
Efficacy and Biological Effect of NCs
When applied to H1299 cells, LBL-Se-NCs had a clear toxic effect,
which was not observed when the cells were treated with siRNA
chitosan complexes without Se core (CS-NCs). Furthermore,
LBL-Se-NCs were found to selectively induce apoptosis in H1299
but not, or much less, in NIH/3T3 normal cells. Also, the uptake
levels of LBL-Se-NCs in NIH/3T3 cells were remarkably lower
than those in H1299 cells. Altogether, the selective anticancer
effect of the LBL-Se-NCs in H1299 cancer cells could be
confirmed, which can be directly linked to apoptosis induction
in cancer cells by Se.
In addition to this selective apoptosis, we evaluated the
intracellular delivery of the developed LBL-Se-NCs in this study
by evaluating the eGFP knockdown efficacy in H1299 cells. We
found that LBL-Se-NCs induced similar knockdown levels as
commercial transfection reagents like jetPEI and Lipofectamine,
which confirms their high transfection efficiency. Interestingly,
transfection efficiencies could be perfectly correlated with the
endosomal escape efficiency of the various NCs (Figures 5A–
D). Furthermore, and importantly, unlike the commercial
transfection reagents or CS-NCs, LBL-Se-NCs were still as
functional as just after synthesis even after 7 days, which is yet
another demonstration of the superior stability of this system.
CONCLUSION
Herein, LBL-Se-NCs were successfully prepared using a simple
layer-by-layer electrostatic assembly of siRNA and chitosan
on Se@CS core nanoparticles. The first layer of chitosan
functioned as an anchoring substrate for siRNA. A third and
final CS layer was added as a protective layer, which provided
outstanding colloidal stability for at least 20 d, which showed no
variation in size or zeta potential irrespective of the suspension
medium. Furthermore, the final CS layer ensured stable siRNA
complexation with only 35% release 7 days post-synthesis, which
was significantly better than CS-NCs. LBL-Se-NCs were found to
selectively induce 32% apoptosis in H1299 cancer cells, which
was 5.7 times more than that in NIH/3T3 normal cells. We
could prove that this effect is linked to the presence of the
Se core, since CS-NCs showed low levels of apoptosis in both
cancerous and normal cells. LBL-Se-NCs were also found to be
able to induce 35% downregulation of eGFP in H1299 cells, which
was the case both just after synthesis and 7 days post-synthesis.
This clearly showed the superior stability of the presented LBL
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nanocarriers herein, as all the other carriers (i.e., CS-NCs, jetPEI
polyplexes, and Lipofectamine lipoplexes) completely lost their
efficacy over time.
In conclusion, the induction of selective apoptosis and
the improved siRNA silencing over extended periods of time
make LBL-Se-NCs an excellent candidate as an off-the-shelf
formulation with a dual mode of action against cancer cells.
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